权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Implantable Bio-Artificial Pancreas (iBAP)

植入式生物人工胰腺 (iBAP)

基本信息

批准号：
9418357
负责人：
SHUVO ROY
金额：
$ 79.25万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-26 至 2020-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9418357
关键词：
Affect Allogenic American Antibodies Area Arteries Beta Cell Biological Response Modifiers Blood Blood Pressure Blood flow Caliber California Catheters Cell Density Cell Membrane Permeability Cell Survival Cell membrane Cells Characteristics Complement Convection Devices Diabetes Mellitus Diffusion Dose Drops Encapsulated Family suidae Geometry Glucose Healthcare Systems Hour Immune Immunosuppression In Vitro Injection of therapeutic agent Insulin Insulin-Dependent Diabetes Mellitus Islets of Langerhans Transplantation Kidney Kinetics Legal patent Mechanics Membrane Modeling Nutrient Organ Outcome Oxygen Pancreas Pancreas Transplantation Patients Performance Permeability Physiological Polymers Production Quality of life San Francisco Silicon Source Stem cells Supporting Cell Testing Tissue Donors Ultrafiltration Universities Veins base biomaterial compatibility clinical translation clinically relevant common treatment cost cytokine design diabetic fasting glucose glucose monitor glycemic control human embryonic stem cell implantation improved in vivo insulin secretion islet multidisciplinary nanopore pancreas development pre-clinical pressure prevent prototype quantum research clinical testing scaffold solute success

项目摘要

Project Summary Approximately 3 million Americans and around 24 million people worldwide are affected by Type 1 Diabetes (T1D). Glucose monitoring followed by insulin injection, allogeneic whole organ pancreas transplantation, and allogeneic islet transplantation are the most common treatments for T1D. These treatments can achieve glycemic control for many patients but result in serious complications. A bioartificial pancreas is a promising treatment for T1D because it contains functional islets. However, previous attempts to develop a bioartificial device have been severely limited by insufficient mass transfer and a limited supply of beta cells. Dr. Shuvo Roy (PI) has developed silicon nanopore membranes (SNM) to achieve high-efficiency blood ultrafiltration while selectively retaining specific solutes for the Bioartificial Kidney project and this project's successes are directly transferrable to the implantable bioartificial pancreas (the iBAP). The ultra-high hydraulic permeability characteristic of the SNM will enable appropriate mass transport (especially oxygen, glucose, and insulin) within to achieve optimal beta cell performance, while the ultra-selective pore characteristic of the SNM enable unprecedented immunoisolation. Also the iBAP will utilize a human embryonic stem cell derived fully functional beta cell that provides and unlimited supply of beta cells for iBAP development and clinical translation.

项目摘要大约有300万美国人和全世界大约2400万人受到1型糖尿病的影响（T1D）。胰岛素注射后血糖监测，同种异体全器官胰腺移植，同种异体胰岛移植是T1D最常见的治疗方法。这些治疗可以达到许多患者的血糖控制，但导致严重的并发症。生物人工胰腺是一种很有前途的治疗T1D，因为它含有功能性胰岛。然而，以前试图开发一种生物人工装置受到质量传递不足和β细胞供应有限的严重限制。舒沃医生罗伊（PI）开发了硅纳米孔膜（SNM），以实现高效血液超滤同时选择性地保留生物人工肾项目的特定溶质，该项目的成功是可直接转移到可植入的生物人工胰腺（iBAP）。超高渗透率 SNM的特性将使适当的质量传输（特别是氧气，葡萄糖和胰岛素）以实现最佳的β细胞性能，而SNM的超选择性孔特性使前所未有的免疫隔离此外，iBAP将利用人类胚胎干细胞衍生的全功能为iBAP开发和临床转化提供无限供应的β细胞。